The UK’s dedicated event that offers a comprehensive program on the latest innovations in imaging diagnosis and treatment.
Young people with Batten Disease will now be offered a drug to slow the onset of sickness, after NHS England and the manufacturer Biomarin agreed a fair price.
Batten Disease is an incurable illness which affects the nervous system, causing seizures, visual impairment, mobility loss and early death. It usually starts in childhood, with an estimated 25 – 40 children living with the condition in England.
The NHS will now be able rapidly to offer the cerliponase alfa treatment to sufferers not currently receiving treatment, by Christmas at the latest.
Simon Stevens, NHS England chief executive, said: “This is another concrete step towards ensuring NHS patients with rare conditions get access to important new treatments. Over recent months there’ve been a series of successful deals as NHS England works closely with the life sciences sector to make life changing new drugs available for haemophilia, MS, rare cancers and other conditions. Coming after extended negotiation, the new deal reached today is a reminder that in order to succeed, companies must be flexible and realistic, because the NHS in England cannot and will not simply write blank cheques at taxpayers’ expense.”
Mid Cheshire NHS Trust’s ageing IT estate was causing significant problems. Amy Freeman, the Trust’s Associate Director of IT, identified a number of challenges that needed to be addressed when she joined the organisation in 2016.